AbbVie SVP uses 2,692 shares for tax withholding

AbbVie Inc. senior vice president and controller David Ryan Purdue reported a tax-related share disposition.

Rhea-AI Filing Summary

AbbVie Inc. senior vice president and controller David Ryan Purdue reported a tax-related share disposition. On February 27, 2026, he transferred 2,692 shares of AbbVie common stock at $232.08 per share to cover tax obligations, described as a payment of tax liability by delivering securities.

After this transaction, he directly owned 7,884 shares of AbbVie common stock. He also had an indirect holding of 543 shares through a profit sharing trust, with a footnote noting this balance in an AbbVie savings program as of February 20, 2026, including shares acquired via a dividend reinvestment feature.

Insider Trade Summary

Exercise Price or Tax Liability: 2,692 shares

Exercise Price or Tax Liability 2 txns

Insider Purdue David Ryan

Role SVP, Controller

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock, $0.01 par value	2,692	$232.08	$625K
holding	Common Stock, $0.01 par value	--	--	--

Holdings After Transaction: Common Stock, $0.01 par value — 7,884 shares (Direct); Common Stock, $0.01 par value — 543 shares (Indirect, Profit sharing trust)

Footnotes (1)

1. F1. Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AbbVie (ABBV) report for David Ryan Purdue?

AbbVie reported that SVP and controller David Ryan Purdue disposed of 2,692 shares of common stock on February 27, 2026. The disposition was for tax withholding, using shares to satisfy a tax liability rather than an open-market sale.

At what price were David Ryan Purdue’s AbbVie (ABBV) shares used for tax withholding?

The 2,692 AbbVie shares were valued at $232.08 per share for the tax-withholding disposition. This reflects the price applied to calculate the number of shares needed to cover the tax obligation in this Form 4 transaction.

How many AbbVie (ABBV) shares does David Ryan Purdue hold after this Form 4 filing?

After the reported tax-withholding transaction, David Ryan Purdue directly owns 7,884 AbbVie common shares. He also has an indirect holding of 543 shares through a profit sharing trust, according to the ownership details in the Form 4.

What is the nature of David Ryan Purdue’s indirect AbbVie (ABBV) share ownership?

His indirect ownership consists of 543 AbbVie common shares held through a profit sharing trust. A footnote explains this balance is in an AbbVie savings program as of February 20, 2026, and includes shares acquired via dividend reinvestment.

Does the AbbVie (ABBV) Form 4 show an open-market sale by David Ryan Purdue?

The Form 4 lists a disposition coded “F,” indicating payment of a tax liability by delivering securities. This reflects tax withholding using AbbVie shares, not a traditional open-market sale initiated for investment or portfolio reasons.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:10 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Purdue David Ryan

(Last) (First) (Middle)

1 NORTH WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Controller

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/27/2026		F		2,692	D	$232.08	7,884	D
Common Stock, $0.01 par value								543(1)	I	Profit sharing trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.

	/s/ T.O. Odutayo, Attorney-in-Fact for David R. Purdue	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.